2018 Distinguished Faculty

  • Gregory P. Adams, PhD, CSO, Eleven Biotherapeutics
  • Hayat Bähr-Mahmud, PhD, Scientist, Bispecific Antibodies, BioNTech AG
  • Lucas Bailey, PhD, Principal Scientist, Protein Engineering, Invenra
  • Roy D. Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck, Sharpe & Dohme (MSD)
  • Jessica Carmen, PhD, Director, Marketing, Cell Therapy, MaxCyte, Inc.
  • Mark Cragg, PhD, Professor, Experimental Cancer Biology, Antibody & Vaccine Group, Cancer Sciences Unit, University of Southampton
  • Scott Cribbes, PhD, Director, Applications and Emerging Technologies, Nexcelom Biosciences LLC
  • Reno Debets, PhD, Associate Professor, Tumor Immunology, Medical Oncology, Erasmus MC Cancer Institute
  • Gregory Driessens, PhD, Project Leader & Head, in vivo Pharmacology, iTeos Therapeutics
  • Margot El-Khouri, PhD, Immunology Sales Specialist, Sales, ProImmune 
  • Peter Emtage, PhD, CSO, R&D, Cell Design Labs
  • Boris Engels, PhD, Senior Investigator, Exploratory Immuno-Oncology, Novartis, Inc.
  • Denise L. Faustman, MD, PhD, Director, Immunobiology, Massachusetts General Hospital; Associate Professor, Medicine, Harvard Medical School
  • Björn Frendéus, PhD, CSO, Research, BioInvent
  • Kurt R. Gehlsen, PhD, Vice President and CSO, Therapeutics, Research Corporation Technologies, Inc.
  • Richard Godfrey, CEO, BerGenBio ASA
  • Abdel Halim, PharmD, PhD, DABCC, FACB, Vice President, Translational Medicine, Biomarkers and Diagnostics, R&D, Celldex Therapeutics
  • John Haurum, PhD, CEO, F-star Biotechnology Ltd.
  • Robert Hawkins, MB BS, MRCP, PhD, FRCP, Cancer Research UK Professor, Medical Oncology, University of Manchester & Honorary Consultant, Medical Oncology, Christie Hospital
  • Tom Holdich, MBBS, Head, Global Medical Affairs & EU Clinical Development, Clinical Research, Adaptimmune
  • Bent Jakobsen, PhD, CSO, Immunocore
  • Ian Johnston, PhD, Industrial and Academic Cooperations Manager, Research & Development, Miltenyi Biotec GmbH
  • Teemu Junttila, PhD, Senior Scientist, Translational Oncology, Genentech, Inc.
  • Jeong Kim, PhD, Scientist & Group Leader, Genentech, Inc.
  • Christian Klein, PhD, Distinguished Scientist, Head, Oncology Programs, Cancer Immunotherapy Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich
  • David G. Kugler, PhD, Senior Scientist, Team-Lead, T Cell Profiling, Juno Therapeutics, Inc.
  • Sean Lim, MB, ChB, PhD, Associate Professor and Honorary Consultant, Haematological Oncology, Antibody & Vaccine Group, Cancer Sciences Unit, University of Southampton
  • John Maher, FRCPath, PhD, Consultant & Senior Lecturer, Immunology, Cancer Studies, King’s College London
  • Krzysztof Masternak, PhD, Head, Biology, Research, Novimmune SA
  • J. Joseph Melenhorst, PhD, Director, Product Development & Correlative Sciences, Center for Cellular Immunotherapies, University of Pennsylvania
  • Paul Moore, PhD, Vice President, Cell Biology and Immunology, Macrogenics, Inc.
  • Richard Morgan, PhD, Vice President, Immunotherapy, bluebird bio
  • Virginie Naegele, PhD, Senior Scientist, BiTE Technology, Amgen Research (Munich) GmbH
  • Shane Olwill, PhD, Vice President, Development; Head, Immuno-Oncology, Pieris Pharmaceutical GmbH
  • Niv Papo, PhD, Group Leader, Biotechnology Engineering, Ben Gurion University of the Negev
  • Sébastien Paris, PhD, Head, Biology, Non-Clinical, Discovery, Nanobiotix
  • Laurent Poirot, PhD, Head, Early Discovery, Innovation, Cellectis
  • Yan Qu, PhD, Senior Principal Scientist, Rinat Pfizer  
  • Sergio A. Quezada, PhD, Professorial Research Fellow, Research Department of Haematology, UCL Cancer Institute
  • Johanna Rühmann, PhD, Senior Director, Internal Project Strategy & Cooperations, Glycotope GmbH
  • Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine  
  • Eric L. Smith, MD, PhD, Assistant Attending, Myeloma & Director, Clinical Translation, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
  • Stephanie Staelens, PhD, Senior Scientist, Technology, Ablynx
  • David Szymkowski, PhD, Senior Research Director, Biotherapeutics, Xencor, Inc.
  • Fiona Thistlethwaite, MB, PhD, Consultant, Medical Oncology, The Christie NHS Foundation Trust
  • Simon Thomas, PhD, MBioch, Associate Director, Immunobiology, R&D, Autolus Ltd.
  • Frederic Triebel, MD, PhD, CSO & CMO, Immutep S.A.
  • Maria Wendt, PhD, Head, Science, Genedata
  • Ann White, PhD, Senior Principal Scientist, New Medicines, UCB
  • Robert W. Wilkinson, PhD, Director, Oncology Research, MedImmune Ltd.
  • K. Dane Wittrup, PhD, Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
  • LiuSong Yin, PhD, Vice Director, Department of Antibody, GenScript

Register Now

Modulating the Tumour Microenvironment